Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells

Pharmaceutical Research

Volumn 25, Issue 5, 2008, Pages 1037-1042

  Nishio, Naoki ^a   Katsura, Toshiya ^a   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

3,5,3 L triiodothyronine; Caco 2 cells; Digoxin; P glycoprotein

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; LIOTHYRONINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; HORMONAL REGULATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT, ACTIVE; BLOTTING, WESTERN; CACO-2 CELLS; CARDIOTONIC AGENTS; CYCLOSPORINE; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID HORMONES; TRIIODOTHYRONINE;

EID: 42049110217     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9495-x     Document Type: Article

References (30)

1. J. H. Lin and M. Yamazaki. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42:59-98 (2003).
2. B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).
3. M. Demeule, J. Jodoin, E. Beaulieu, M. Brossard, and R. Beliveau. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS. Lett. 442:208-214 (1999).
4. S. Micuda, L. Mundlova, J. Mokry, J. Osterreicher, J. Cermanova, D. Cizkova, and J. Martinkova. The effect of mdr1 induction on the pharmacokinetics of rhodamine 123 in rats. Basic Clin. Pharmacol. Toxicol. 96:257-258 (2005).
5. P. G. Wells, J. Feely, G. R. Wilkinson, and A. J. Wood. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing. Clin. Pharmacol. Ther. 33:603-608 (1983).
6. J. R. Lawrence, D. J. Sumner, W. J. Kalk, W. A. Ratcliffe, B. Whiting, K. Gray, and M. Lindsay. Digoxin kinetics in patients with thyroid dysfunction. Clin. Pharmacol. Ther. 22:7-13 (1977).
7. G. M. Shenfield, J. Thompson, and D. B. Horn. Plasma and urinary digoxin in thyroid dysfunction. Eur. J. Clin. Pharmacol. 12:437-443 (1977).
8. J. Bonelli, H. Haydl, K. Hruby, and G. Kaik. The pharmacokinetics of digoxin in patients with manifest hyperthyroidism and after normalization of thyroid function. Int. J. Clin. Pharmacol. Biopharm. 16:302-306 (1978).
9. G. M. Shenfield. Influence of thyroid dysfunction on drug pharmacokinetics. Clin. Pharmacokinet. 6:275-297 (1981).
10. N. Nishio, T. Katsura, K. Ashida, M. Okuda, and K. Inui. Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab. Dispos. 33:1584-1587 (2005).
11. W. Siegmund, S. Altmannsberger, A. Paneitz, U. Hecker, M. Zschiesche, G. Franke, W. Meng, R. Warzok, E. Schroeder, B. Sperker, B. Terhaag, I. Cascorbi, and H. K. Kroemer. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin. Pharmacol. Ther. 72:256-264 (2002).
12. K. Ashida, T. Katsura, H. Motohashi, H. Saito, and K. Inui. Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 282:G617-623 (2002).
13. H. H. Samuels, F. Stanley, and J. Casanova. Depletion of l-3,5,3′-triiodothyronine and l-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology 105:80-85 (1979).
14. S. Masuda, S. Uemoto, T. Hashida, Y. Inomata, K. Tanaka, and K. Inui. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 68:98-103 (2000).
15. K. Westphal, A. Weinbrenner, M. Zschiesche, G. Franke, M. Knoke, R. Oertel, P. Fritz, O. von Richter, R. Warzok, T. Hachenberg, H. M. Kauffmann, D. Schrenk, B. Terhaag, H. K. Kroemer, and W. Siegmund. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:345-355 (2000).
16. D. Durr, B. Stieger, G. A. Kullak-Ublick, K. M. Rentsch, H. C. Steinert, P. J. Meier, and K. Fattinger. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604 (2000).
17. L. Jette, E. Beaulieu, J. M. Leclerc, and R. Beliveau. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am. J. Physiol. 270:F756-765 (1996).
18. J. Y. Zhao, M. Ikeguchi, T. Eckersberg, and M. T. Kuo. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133:521-528 (1993).
19. K. V. Chin, S. S. Chauhan, I. Pastan, and M. M. Gottesman. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1:361-365 (1990).
20. R. C. Ribeiro, J. W. Apriletti, B. L. West, R. L. Wagner, R. J. Fletterick, F. Schaufele, and J. D. Baxter. The molecular biology of thyroid hormone action. Ann. N. Y. Acad. Sci. 758:366-389 (1995).
21. K. Ashida, T. Katsura, H. Saito, and K. Inui. Decreased activity and expression of intestinal oligopeptide transporter PEPT1 in rats with hyperthyroidism in vivo. Pharm. Res. 21:969-975 (2004).
22. C. J. Torrance, J. E. Devente, J. P. Jones, and G. L. Dohm. Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. Endocrinology 138:1204-1214 (1997).
23. M. Matosin-Matekalo, J. E. Mesonero, T. J. Laroche, M. Lacasa, and E. Brot-Laroche. Glucose and thyroid hormone co-regulate the expression of the intestinal fructose transporter GLUT5. Biochem. J. 339(Pt 2):233-239 (1999).
24. J. Huuskonen, M. Vishnu, C. R. Pullinger, P. E. Fielding, and C. J. Fielding. Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 43:1626-1632 (2004).
25. R. A. Giannella, J. Orlowski, M. L. Jump, and J. B. Lingrel. Na(+)-K(+)-ATPase gene expression in rat intestine and Caco-2 cells: response to thyroid hormone. Am. J. Physiol. 265:G775-782 (1993).
26. 1 regulates expression of the Na+/H+ exchanger (NHE1). J. Biol. Chem. 277:28656-28662 (2002).
27. P. O'Connor and J. Feely. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin. Pharmacokinet. 13:345-364 (1987).
28. H. R. Ochs, D. J. Greenblatt, H. J. Kaschell, U. Klehr, M. Divoll, and D. R. Abernethy. Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. Br. J. Clin. Pharmacol. 12:829-832 (1981).
29. M. Jin, T. Shimada, M. Shintani, K. Yokogawa, M. Nomura, and K. Miyamoto. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Drug Metab. Pharmacokinet. 20:324-330 (2005).
30. T. Mitin, L. L. von Moltke, M. H. Court, and D. J. Greenblatt. Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. Drug Metab. Dispos. 32:779-782 (2004).